Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Investigating a Shortened Course of Radiation Therapy for Soft Tissue Sarcomas Arising in the Abdomen and/or Pelvis, MARS Trial

Trial Status: active

This phase II trial evaluates the safety of delivering hypo-fractionated radiation therapy before surgery for treating patients with sarcomas of the abdomen or pelvis (abdominopelvic) or sarcoma of the abdomen or pelvis that has come back after a period of improvement (recurrent). Receiving radiation therapy followed by surgery for sarcomas of the abdomen or pelvis is standard of care treatment option for patients. However, standard radiation therapy consists of five to six weeks of daily radiation, which is a significant burden for patients. Hypo-fractionated radiation therapy is a type of radiation therapy in which the total prescribed dose of radiation is delivered in fewer but larger hypo-fractionated doses compared to standard radiation therapy. The safety of hypo-fractionated radiation therapy has been well established for other types of cancers but is not well-established for sarcomas of the abdomen or pelvis. Giving hypo-fractionated radiation therapy may be an effective treatment option for treating patients with sarcomas of the abdomen or pelvis or recurrent sarcomas of the abdomen or pelvis.